Yuyu Pharma Presents Two Scientific Abstracts at ARVO Examining Novel Peptide YP-P10 for Dry Eye Disease
Yuyu Pharma announced the presentation of two scientific abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting, taking place in New Orleans, LA, April 23-27, 2023.
"At Yuyu, we are grateful for the opportunity to collaborate with experts in ophthalmology to perform meaningful research around YP-P10, our novel peptide, currently in phase 2 clinical trials for treatment of dry eye disease. Thre presentations at ARVO are an opportunity to showcase to preclinical data that supported Yuyu's decision to develop YP-P10 for dry eye disease as we await YP=P10's topline clinical data anticipated to be released later this month," Robert Yu, Yuya Pharma, said in a company news release.
Presenter: Laxmikant (Neil) Gharat, PhD, Yuyu Pharma
Session: Dry Eye
Date / Time: Sun, April 23, 2023, 12:00 PM to 1:45 PM
Purpose: YP-P10 Peptide is a synthetic anti-inflammatory peptide which has shown reduction in inflammatory cytokines and chemokines in stimulated in-vitro hPBMC’s and human corneal epithelial cells. This study is aimed to investigate the effect of YP-P10 Peptide in a mouse model of dry eye disease in comparison to lifitegrast, cyclosporine, diquafosol sodium, and hyaluronic acid.
Presentation
YP-P10 Peptide selectively decreased Th2 and Th17 cells in an in vitro model of human blood-derived effector CD4+T-cell subsets.
Presenter: Virginia L. Calder, PhD, University College London
Session: The Role of Infiltrating Immune Cells in Ocular Disease
Date / Time: Wed, April 26, 2023, 10:30 AM to 12:30 PM
Purpose: A synthetic peptide YP-P10 has previously been demonstrated to exert a protective role in in vivo models of dry eye disease (DED) and is in a phase 2 study for DED. The purpose of this study is to investigate YP-P10 Peptide for its anti-inflammatory effect(s) on adaptive immune cell responses in vitro and elucidate its mechanism of action.
YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties being explored for the potential treatment of dry eye disease (DED). In April 2022, Yuyu received clearance from the FDA that enabled the company to initiate the phase 2 clinical study, ICECAP, to evaluate the safety, tolerability and efficacy of YP-P10 Ophthalmic Solution in patients with DED. ICECAP is Yuyu’s first biopharmaceutical clinical trial within the United States.